阿利西尤单抗对急性冠脉综合征后死亡率的影响
ODYSSEY OUTCOMES 试验纳入 18 924 例近期急性冠脉综合征且强化他汀治疗后致动脉粥样硬化脂蛋白仍升高的患者,随机比较阿利西尤单抗与安慰剂。中位随访 2.8 年,阿利西尤单抗组全因死亡 334 例(3.5%),安慰剂组 392 例(4.1%)(HR 0.85,95%CI 0.73–0.98,P=0.03)。预设分析中随访≥3 年患者死亡风险降低(HR 0.78,95%CI 0.65–0.94,P=0.01)。
要点
- 阿利西尤单抗使急性冠脉综合征后全因死亡风险降低 15%。
- 随访≥3 年者死亡风险降低更明显(HR 0.78)。
- 基线 LDL-C≥100 mg/dL 者死亡绝对风险更高且获益更大。
核心结论
- 在强化他汀治疗基础上加用阿利西尤单抗可能降低急性冠脉综合征后的死亡风险。
研究设计与样本
- ODYSSEY OUTCOMES 为双盲随机对照试验,纳入 18 924 例 1–12 个月前发生急性冠脉综合征且强化他汀治疗后致动脉粥样硬化脂蛋白仍升高的患者。
- 阿利西尤单抗剂量盲法滴定至目标 LDL-C 25–50 mg/dL。
- 中位随访 2.8 年,采用 log-rank 检验分析全因死亡、心血管死亡和非心血管死亡。
主要发现
- 阿利西尤单抗组全因死亡 334 例(3.5%),安慰剂组 392 例(4.1%)(HR 0.85,95%CI 0.73–0.98,P=0.03,名义 P 值)。
- 心血管死亡阿利西尤单抗组 240 例(2.5%)vs 安慰剂组 271 例(2.9%)(HR 0.88,95%CI 0.74–1.05,P=0.15)。
- 非心血管死亡阿利西尤单抗组 94 例(1.0%)vs 安慰剂组 121 例(1.3%)(HR 0.77,95%CI 0.59–1.01,P=0.06)。
- 预设分析中 8242 例符合≥3 年随访的患者,阿利西尤单抗降低死亡(HR 0.78,95%CI 0.65–0.94,P=0.01)。
- 事后分析显示基线 LDL-C≥100 mg/dL(2.59 mmol/L)者较基线 LDL-C 较低者死亡绝对风险更高且阿利西尤单抗获益更大(HR 0.71,95%CI 0.56–0.90,Pinteraction=0.007)。
关键数值与推荐
- 阿利西尤单抗组 4 个月时达到的 LDL-C 越低,全因死亡越少,直至约 30 mg/dL(线性趋势调整 P=0.017)。
- 发生非致命心血管事件的患者心血管死亡和非心血管死亡风险均增加(P<0.0001)。
临床怎么用
- 对于急性冠脉综合征后强化他汀治疗仍脂质异常的患者,可考虑加用阿利西尤单抗以降低死亡风险。
- 治疗维持≥3 年、基线 LDL-C≥100 mg/dL 或达到较低 LDL-C 水平时死亡获益可能更明显。
局限性
- 全因死亡获益为名义 P 值,心血管和非心血管死亡组分差异未达统计学显著性。
- ≥3 年随访分析和基线 LDL-C 亚组分析分别为预设分析和事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. METHODS: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. RESULTS: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths ( P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events ( P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined with achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). CONCLUSIONS: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01663402.
引用
- Steg PG, Szarek M, Bhatt DL, et al. Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation. 2019. PMID: 31117810. doi:10.1161/CIRCULATIONAHA.118.038840
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。